- Home
- Knowledge library
- Economics of health and welfare
Economics of health and welfare
Summary
Results summary:
The report outlines the literature relevant to five endemic diseases of beef cattle and sheep. In each case costs of the disease are presented alongside the cost benefit of controlling that disease.
Below is a summary of the main conclusions.
Table 1: Summary of diseases in English flock and herd
Disease |
Page |
Cost of disease to industry per year |
Reference |
Cost of disease per affected animal £ per animal (Calculated in this report) |
Cost benefit of disease prevention £ per animal in flock or herd (Calculated in this report) |
Sheep | |||||
Lameness | 12 |
£24 million to British sheep industry |
Nieuwohf and Bishop, 2005 |
90 (per ewe) |
4.40 (per ewe) |
Abortion | 15 |
£32 million to UK sheep industry |
Bennett and Ijpelaar, 2003 |
122 (per ewe) |
10.90 (per ewe) |
Ectoparasite (scab) | 17 |
£8.3 million to British sheep industry |
Nieuwohf and Bishop, 2005 |
12.30 (per ewe) |
10.50 (per ewe) |
Intestinal parasites stomach worms | 19/20 |
£84 million to British sheep industry |
Nieuwohf and Bishop, 2005 |
4.40 (per lamb) |
3.50 (per lamb) |
Liver fluke | 22 |
£13-15 million for English beef and sheep |
Eblex Stock Briefing, 2011 |
6 (per lamb) |
5.60 (per lamb) |
Cattle | |||||
BVD | 28 |
£36.6 million to UK cattle industry |
Bennett and Ijpelaar, 2003 |
58 (per cow) |
42 (per cow) |
Johne’s | 32 |
£13 million UK cattle industry |
Caldow and Gunn 2009 |
46 (per cow) |
|
Respiratory Disease | 33 |
£50 million UK cattle industry |
Potter, 2010 |
82 (per calf) |
76 (per calf) |
Diarrhoea (calf scour) | 35 |
£11 million to UK cattle industry |
Bennett and Ijpelaar, 2003 |
58 (per calf) |
47 (per calf) |
Liver fluke | 36 |
£23 million to UK cattle industry |
Bennett and Ijpelaar, 2003 |
90 (per calf) |
87 (per calf) |
All the costs calculated in this project are based on practically realistic examples but will vary according to the severity of an outbreak and promptness of treatment.
Planned activity:
- This report will be used to underpin knowledge transfer messages to producers about the cost benefit of controlling endemic disease in their flock or herd
- The report will be used to inform the priorities of the R&D strategy and future calls under this theme
- The information will be communicated to industry via press releases and the EBLEX producer bulletin etc.
- It will also be used to communicate to stakeholders and opinion formers about the potential cost of animal health & welfare to the beef and sheep industry
Downloads
74106 Final Report Apr 2013About this project
The Problem:
It is widely acknowledged that sub-optimal health and welfare represents a major cost to the English beef and sheep industry. EBLEX acknowledge this is an area where R&D and KT investment can have significant impact. In order to strengthen the evidence base that informs such investment decisions a document that sets out the cost of the main animal health threats to the industry and how these might change in the future is required.
Project Aims :
The main objective of this work is to provide Eblex with independent evidence on which to base future funding decisions on research and development and knowledge transfer to maximise benefit to levy payers.
Approach:
This will be a desk based study including a literature review and consultation with relevant industry representatives and organisations.
Deliverables :
- The production of a literature review to collate the most recent estimates of the economic impact of the major animal health and welfare issues and threats to beef and sheep production in England (at a country and farm level)
- An analysis of the potential future changes in animal health and welfare issues as the wider environment changes (STEEPLE analysis)
- Recommendations for how R&D investment from EBLEX can make a difference to these issues over the next 10 years, including a cost benefit analysis where possible
Recommendations for how KT investment from EBLEX can make a difference to these issues over the next 10 years, including a cost benefit analysis where possible.